703 related articles for article (PubMed ID: 23917401)
1. The integrated landscape of driver genomic alterations in glioblastoma.
Frattini V; Trifonov V; Chan JM; Castano A; Lia M; Abate F; Keir ST; Ji AX; Zoppoli P; Niola F; Danussi C; Dolgalev I; Porrati P; Pellegatta S; Heguy A; Gupta G; Pisapia DJ; Canoll P; Bruce JN; McLendon RE; Yan H; Aldape K; Finocchiaro G; Mikkelsen T; Privé GG; Bigner DD; Lasorella A; Rabadan R; Iavarone A
Nat Genet; 2013 Oct; 45(10):1141-9. PubMed ID: 23917401
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.
Kadioglu O; Saeed MEM; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Life Sci; 2021 Nov; 284():119601. PubMed ID: 33991550
[TBL] [Abstract][Full Text] [Related]
3. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
4. Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation.
Furgason JM; Li W; Milholland B; Cross E; Li Y; McPherson CM; Warnick RE; Rixe O; Stambrook PJ; Vijg J; Bahassi el M
Mutagenesis; 2014 Sep; 29(5):341-50. PubMed ID: 25103728
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
6. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
Klingler-Hoffmann M; Fodero-Tavoletti MT; Mishima K; Narita Y; Cavenee WK; Furnari FB; Huang HJ; Tiganis T
J Biol Chem; 2001 Dec; 276(49):46313-8. PubMed ID: 11514572
[TBL] [Abstract][Full Text] [Related]
7. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
8. LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL.
Ko A; Hasanain M; Oh YT; D'Angelo F; Sommer D; Frangaj B; Tran S; Bielle F; Pollo B; Paterra R; Mokhtari K; Soni RK; Peyre M; Eoli M; Papi L; Kalamarides M; Sanson M; Iavarone A; Lasorella A
Cancer Discov; 2023 Mar; 13(3):702-723. PubMed ID: 36445254
[TBL] [Abstract][Full Text] [Related]
9. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy.
Skoda J; Neradil J; Zitterbart K; Sterba J; Veselska R
Oncol Rep; 2014 Jan; 31(1):480-7. PubMed ID: 24270553
[TBL] [Abstract][Full Text] [Related]
10. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Verhaak RG; Hoadley KA; Purdom E; Wang V; Qi Y; Wilkerson MD; Miller CR; Ding L; Golub T; Mesirov JP; Alexe G; Lawrence M; O'Kelly M; Tamayo P; Weir BA; Gabriel S; Winckler W; Gupta S; Jakkula L; Feiler HS; Hodgson JG; James CD; Sarkaria JN; Brennan C; Kahn A; Spellman PT; Wilson RK; Speed TP; Gray JW; Meyerson M; Getz G; Perou CM; Hayes DN;
Cancer Cell; 2010 Jan; 17(1):98-110. PubMed ID: 20129251
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
Thomas C; Ely G; James CD; Jenkins R; Kastan M; Jedlicka A; Burger P; Wharen R
Acta Neuropathol; 2001 Jun; 101(6):605-15. PubMed ID: 11515790
[TBL] [Abstract][Full Text] [Related]
12. Updated Insights on EGFR Signaling Pathways in Glioma.
Oprita A; Baloi SC; Staicu GA; Alexandru O; Tache DE; Danoiu S; Micu ES; Sevastre AS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435537
[TBL] [Abstract][Full Text] [Related]
13. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
14. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
15. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
Schmidt EE; Ichimura K; Goike HM; Moshref A; Liu L; Collins VP
J Neuropathol Exp Neurol; 1999 Nov; 58(11):1170-83. PubMed ID: 10560660
[TBL] [Abstract][Full Text] [Related]
16. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
Di K; Linskey ME; Bota DA
Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
18. Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.
Patanè M; Porrati P; Bottega E; Morosini S; Cantini G; Girgenti V; Rizzo A; Eoli M; Pollo B; Sciacca FL; Pellegatta S; Finocchiaro G
Mol Cancer; 2013 Dec; 12():160. PubMed ID: 24330732
[TBL] [Abstract][Full Text] [Related]
19. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
[TBL] [Abstract][Full Text] [Related]
20. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
